Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Equity Ratio (2021 - 2026)

TriSalus Life Sciences has reported Equity Ratio over the past 6 years, most recently at 0.18 for Q1 2026.

  • For Q1 2026, Equity Ratio rose 115.03% year-over-year to 0.18; the TTM value through Mar 2026 reached 0.18, up 115.03%, while the annual FY2025 figure was 0.96, 11.28% up from the prior year.
  • Equity Ratio for Q1 2026 was 0.18 at TriSalus Life Sciences, up from 0.96 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.25 in Q3 2023 and troughed at 16.21 in Q2 2023.
  • A 5-year average of 2.57 and a median of 0.78 in 2024 define the central range for Equity Ratio.
  • On a YoY basis, Equity Ratio climbed as much as 140.35% in 2023 and fell as far as 2683.27% in 2023.
  • Year by year, Equity Ratio stood at 8.05 in 2022, then surged by 86.34% to 1.1 in 2023, then rose by 1.82% to 1.08 in 2024, then increased by 11.28% to 0.96 in 2025, then skyrocketed by 118.83% to 0.18 in 2026.
  • Business Quant data shows Equity Ratio for TLSI at 0.18 in Q1 2026, 0.96 in Q4 2025, and 0.73 in Q3 2025.